Press Enter to search · ESC to close

US Stocks

Akeso’s Hong Kong Shares Fall 15% After Partner’s Drug Fails FDA Approval

Akeso’s Hong Kong-listed shares fell 15% after its US partner’s new drug failed to win FDA approval. The decline followed the regulatory rejection of the partner company’s drug candidate. Akeso’s Hong Kong shares dropped 15% on the news.

Share

Related News

Cointime share card
Long-press the image to save or share
Pitch us Community Feedback